Modalis Licensed Exegenesis Muscle-Targeting AAV Technology
The partnership aims to improve the delivery of CRISPR-based gene therapies for Duchenne muscular dystrophy.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize patient health over their own profits?
Modalis Therapeutics has licensed the EMC181 engineered AAV capsid from Exegenesis Bio to advance its MDL-201 gene therapy. This research-stage development focuses on delivering CRISPR-GNDM epigenome-editing payloads more effectively to muscle tissue.
Why it matters
The collaboration seeks to overcome common limitations in gene therapy delivery by enhancing muscle tissue targeting while reducing off-target liver exposure. This approach addresses the root cause of Duchenne muscular dystrophy, a condition characterized by a deficiency of dystrophin protein.
The EMC181 engineered AAV capsid is designed to increase gene delivery efficiency to skeletal and other muscle tissue compared to standard viral vectors. It achieves this by reducing systemic exposure in the liver, a common challenge in gene therapy administration.
The players
Exegenesis Bio
A biotech firm based in Horsham, PA, that specializes in AAV capsid engineering and gene-therapy delivery platforms.
Modalis Therapeutics
A Tokyo-based biotechnology company focused on developing CRISPR-based epigenome-editing therapies for genetic diseases.
The details
Exegenesis Bio provides a muscle-targeting AAV (adeno-associated virus) vector, which is a modified, harmless virus used as a delivery vehicle to introduce genetic material into cells. Modalis Therapeutics integrates this with its CRISPR-GNDM (guide nucleotide-directed modulator) epigenome-editing technology, which modifies gene expression without cutting DNA. The combined therapy aims to increase utrophin protein expression, effectively compensating for the dystrophin deficiency that causes Duchenne muscular dystrophy.
Timeline
The licensing agreement was announced on September 21, 2026.
The Tech Race
This deal sits within the broader competitive race to optimize gene therapy delivery for hereditary muscle disorders. It specifically builds on the CRISPR-GNDM epigenome-editing research pipeline to improve therapeutic outcomes beyond existing gene replacement methods.
This development remains at the research stage and will not change current clinical treatment protocols for patients. The collaboration is expected to have an immaterial effect on the companies' current fiscal year results as they work toward advancing the MDL-201 candidate.
The takeaway
The move underscores the industry-wide pivot toward refining delivery vectors to improve gene therapy precision. Watch for upcoming research disclosures regarding the efficacy of MDL-201 in preclinical models to determine if the EMC181 capsid achieves intended gains in muscle-tissue selectivity.
Further reading
For more on the current landscape of genetic medicine, visit our Biotech section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust that pharmaceutical companies prioritize patient health over their own profits?
